Roche Signs a Technology License Agreement with Amunix Pharmaceutical to Develop Non-Oncology Therapies

 Roche Signs a Technology License Agreement with Amunix Pharmaceutical to Develop Non-Oncology Therapies

Shots:

  • Amunix to receive $40M up front, up to $1.5B as development & commercial milestones along with royalties on sales of products. Roche to leverage Amunix’s XTEN technology platform to develop novel non-oncology therapies for undisclosed targets
  • The agreement follows Amunix’s previous technology assessment with Roche which focused on utilizing XTEN to extend the half-life of the drugs
  • Amunix’s XTEN technology platform consists of unstructured polypeptides and has been validated via collaboration with biopharmaceutical companies to extend the half-life of therapies with low associated immunogenicity  

Click here ­to­ read full press release/ article | Ref: GlobeNewswire  | Image: Amunix Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post